Can-Fite Biopharma Ltd Sponsore (CANF) 2.12 $CANF
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
PR Newswire - Mon Apr 20, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CANF: 2.12 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.67 (-0.04), CANF: 2.12 (+0.17), SNTA: 2.97 (+0.01), BCRX: 10.62 (-0.09), GBSN: 4.98 (+1.44), TCK: 12.87 (-0.03), CHTR: 184.88 (-1.93), DANG: 8.96 (+0.06), CLDN: 13.59 (-2.77), REXX: 4.77 (-0.04), MOV: 30.62 (-0.18)
CAN-FITE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Can-Fite BioPharma Ltd. Following Announcement of Psiorasis Drug Trial Results
Business Wire - Mon Mar 30, 9:00PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"
, announces that KSF has commenced an investigation into Can-Fite BioPharma Ltd. (NYSE MKT: CANF).
CANF: 2.12 (+0.17)
Can-Fite BioPharma (CANF) Stock Plummets to 52-Week Low Today on Psiorasis Drug Trial Results
at The Street - Mon Mar 30, 2:07PM CDT
Shares of Can-Fite BioPharma (CANF) plunged to a one-year low on Monday announced that its drug candidate CF101 did not achieve its primary endpoint in a Phase II/III psoriasis trial.
CANF: 2.12 (+0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:45AM CDT
BDSI: 9.26 (+0.12), CTRX: 59.46 (-0.11), ARCW: 7.06 (-0.57), GMAN: 8.63 (-0.17), NCTY: 1.46 (+0.02), ADMP: 4.66 (-0.01), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), PME: 1.88 (-0.12), GENE: 4.88 (-0.05), CANF: 2.12 (+0.17), ICEL: 16.47 (-0.02), CELP: 15.55 (+0.14), PSTR: 4.78 (+0.07), HZNP: 30.96 (+0.10), SMTX: 1.39 (unch), CNET: 1.56 (unch), REFR: 6.30 (unch), AMCO: 1.06 (-0.02), SPKE: 12.97 (+0.09)
Can-Fite's lead product candidate fails in clinical trial; shares plummet 51%
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:43AM CDT
CANF: 2.12 (+0.17)
Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis
PR Newswire - Mon Mar 30, 8:11AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.
CANF: 2.12 (+0.17)
Can-Fite Files 2014 Annual Report on Form 20-F
PR Newswire - Fri Mar 27, 3:29PM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has filed its 2014 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
CANF: 2.12 (+0.17)
Can-Fite inks Canadian distribution deal for lead drug candidate
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 8:52AM CDT
CANF: 2.12 (+0.17), CPHR: 11.34 (+0.44)
Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis
PR Newswire - Mon Mar 23, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company" today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma ("Can-Fite" (NYSE MKT: CANF) (TASE: CFBI) for moderate to severe plaque psoriasis and rheumatoid arthritis.
CANF: 2.12 (+0.17), CPH.TO: 13.67 (+0.29), CPHR: 11.34 (+0.44)
Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals
PR Newswire - Mon Mar 23, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) (TSX: CPH) to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
CANF: 2.12 (+0.17), CPH.TO: 13.67 (+0.29), CPHR: 11.34 (+0.44)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 4:43PM CDT
CANF: 2.12 (+0.17), GES: 18.14 (+0.11), LYB: 97.11 (+0.56), ANTH: 4.79 (+0.10), SCVL: 27.75 (-0.20), EMC: 27.13 (+0.81), WSM: 76.08 (-0.66), NQ: 4.16 (+0.04), SBLK: 3.67 (-0.11), HTA: 27.03 (-0.12)
Can-Fite develops companion test for drug candidates
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:33AM CDT
CANF: 2.12 (+0.17)
Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs
PR Newswire - Wed Mar 18, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has completed the development of a commercial predictive biomarker blood test kit for the A3 adenosine receptor (A3AR). The biomarker test can be used at any molecular biology lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient would benefit from treatment with Can-Fite's drugs, which are currently in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.
CANF: 2.12 (+0.17)
An Introduction To Can-Fite Ahead Of Phase II Psoriasis Data Next Week
Jason Napodano, CFA - at Seeking Alpha - Tue Mar 17, 3:09PM CDT
CANF: 2.12 (+0.17)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.12 (+0.17), AGN: 240.22 (+2.88), ACAD: 38.55 (-0.20), ITEK: 4.80 (-0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), CBMG: 32.14 (+2.21)
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
PR Newswire - Mon Apr 20, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CANF: 2.12 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.67 (-0.04), CANF: 2.12 (+0.17), SNTA: 2.97 (+0.01), BCRX: 10.62 (-0.09), GBSN: 4.98 (+1.44), TCK: 12.87 (-0.03), CHTR: 184.88 (-1.93), DANG: 8.96 (+0.06), CLDN: 13.59 (-2.77), REXX: 4.77 (-0.04), MOV: 30.62 (-0.18)
CAN-FITE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Can-Fite BioPharma Ltd. Following Announcement of Psiorasis Drug Trial Results
Business Wire - Mon Mar 30, 9:00PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"
, announces that KSF has commenced an investigation into Can-Fite BioPharma Ltd. (NYSE MKT: CANF). CANF: 2.12 (+0.17)
Can-Fite BioPharma (CANF) Stock Plummets to 52-Week Low Today on Psiorasis Drug Trial Results
at The Street - Mon Mar 30, 2:07PM CDT
Shares of Can-Fite BioPharma (CANF) plunged to a one-year low on Monday announced that its drug candidate CF101 did not achieve its primary endpoint in a Phase II/III psoriasis trial.
CANF: 2.12 (+0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:45AM CDT
BDSI: 9.26 (+0.12), CTRX: 59.46 (-0.11), ARCW: 7.06 (-0.57), GMAN: 8.63 (-0.17), NCTY: 1.46 (+0.02), ADMP: 4.66 (-0.01), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), PME: 1.88 (-0.12), GENE: 4.88 (-0.05), CANF: 2.12 (+0.17), ICEL: 16.47 (-0.02), CELP: 15.55 (+0.14), PSTR: 4.78 (+0.07), HZNP: 30.96 (+0.10), SMTX: 1.39 (unch), CNET: 1.56 (unch), REFR: 6.30 (unch), AMCO: 1.06 (-0.02), SPKE: 12.97 (+0.09)
Can-Fite's lead product candidate fails in clinical trial; shares plummet 51%
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:43AM CDT
CANF: 2.12 (+0.17)
Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis
PR Newswire - Mon Mar 30, 8:11AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.
CANF: 2.12 (+0.17)
Can-Fite Files 2014 Annual Report on Form 20-F
PR Newswire - Fri Mar 27, 3:29PM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has filed its 2014 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
CANF: 2.12 (+0.17)
Can-Fite inks Canadian distribution deal for lead drug candidate
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 8:52AM CDT
CANF: 2.12 (+0.17), CPHR: 11.34 (+0.44)
Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis
PR Newswire - Mon Mar 23, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma ("Can-Fite" (NYSE MKT: CANF) (TASE: CFBI) for moderate to severe plaque psoriasis and rheumatoid arthritis. CANF: 2.12 (+0.17), CPH.TO: 13.67 (+0.29), CPHR: 11.34 (+0.44)
Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals
PR Newswire - Mon Mar 23, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) (TSX: CPH) to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
CANF: 2.12 (+0.17), CPH.TO: 13.67 (+0.29), CPHR: 11.34 (+0.44)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 4:43PM CDT
CANF: 2.12 (+0.17), GES: 18.14 (+0.11), LYB: 97.11 (+0.56), ANTH: 4.79 (+0.10), SCVL: 27.75 (-0.20), EMC: 27.13 (+0.81), WSM: 76.08 (-0.66), NQ: 4.16 (+0.04), SBLK: 3.67 (-0.11), HTA: 27.03 (-0.12)
Can-Fite develops companion test for drug candidates
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:33AM CDT
CANF: 2.12 (+0.17)
Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs
PR Newswire - Wed Mar 18, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has completed the development of a commercial predictive biomarker blood test kit for the A3 adenosine receptor (A3AR). The biomarker test can be used at any molecular biology lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient would benefit from treatment with Can-Fite's drugs, which are currently in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.
CANF: 2.12 (+0.17)
An Introduction To Can-Fite Ahead Of Phase II Psoriasis Data Next Week
Jason Napodano, CFA - at Seeking Alpha - Tue Mar 17, 3:09PM CDT
CANF: 2.12 (+0.17)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.12 (+0.17), AGN: 240.22 (+2.88), ACAD: 38.55 (-0.20), ITEK: 4.80 (-0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), CBMG: 32.14 (+2.21)
